Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports results on January 23 for the period ending December 31 2024
The Hyderabad Telangana-based company is expected to report a 12.4% increase in revenue to ₹81.331 billion from ₹72.37 billion a year ago, according to the mean estimate from 20 analysts, based on LSEG data.
LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹16.61 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $17.00, above its last closing price of $14.90.
Previous quarterly performance (using preferred earnings measure in Indian rupees).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | 16.82 | 16.66 | 15.05 | Missed | -9.7 |
Jun. 30 2024 | 15.90 | 15.62 | 16.69 | Beat | 6.9 |
Mar. 31 2024 | 15.30 | 13.68 | 15.67 | Beat | 14.6 |
Dec. 31 2023 | 15.51 | 14.09 | 16.56 | Beat | 17.6 |
Sep. 30 2023 | 14.10 | 13.92 | 17.78 | Beat | 27.8 |
Jun. 30 2023 | 11.36 | 11.44 | 16.87 | Beat | 47.5 |
Mar. 31 2023 | 10.53 | 10.50 | 11.52 | Beat | 9.5 |
Dec. 31 2022 | 9.60 | 9.60 | 14.95 | Beat | 56.9 |
This summary was machine generated January 21 at 11:17 GMT. All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。